A Proof of Concept Study Non-Randomized, Single-Center Pilot Trial Assessing The Safety/Efficacy Of Dual Targeting Of Peripheral And Central Humoral Alloimmune Memory With Anti-CD38 (Daratumumab) And Costimulation Blockade With CTLA4-Ig (Belatacept) In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518128-66-00

Acronym

38RC21.171 COMBAT

Enrollment

Registered

2024-11-08

Start date

2022-01-11

Completion date

2025-04-22

Last updated

2024-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with cPRA or TGI ≥ 95% on the deceased donor kidney transplant waiting list, who have not received a compatible donor offer for ≥1 year.

None listed

Sex/Gender

All

Age

18 Years to No maximum

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026